AMTSL

Active Management of the Third Stage of Labor for the prevention of Postpartum Hemorrhage

Prevention
Prevention
  • PREVENTION
  • DIAGNOSTIC
  • TREATMENT
  • OVERVIEW
  • TECHNOLOGY Characteristics
  • AMTSL
    Oxytocin diluted in a bag of IV fluid

    Global Annual Deaths associated with obstetric hemorrhage

    PERCENT (%)
    NUMBER

    Maternal

    45%
    115,000

    Neonatal

    N/A
    N/A

    Stillbirth

    *
    *
    *Estimates under development

     

    Condition

    Active Management of the Third Stage of Labor (AMTSL) decreases the chance and intensity of postpartum hemorrhage (PPH). Postpartum hemorrhage is the loss of more than half a liter of blood during delivery, and it occurs in about 1 in 10 births accounting for about 100,000 maternal deaths per year. The third stage of labor is the time after the birth of the baby through the delivery of the placenta.

     

    Mechanism of Action

    Active management of the third stage of labor is composed of three steps: the administration of oxytocin or other uterotonics, cord traction to ease placental delivery, and uterine massage. The uterotonic helps the uterus contract which has the dual benefits of helping to deliver the placenta and slow the loss of blood. Similarly, cord traction in coordination with the natural contractions encourages a clean delivery of the placenta. Finally, the uterine massage both encourages clean delivery of the placenta while also helping to ensure against avulsion and uterine inversion.

     

    Current Use in High-Resource Settings

    Active management of the third stage of labor is included in the standard of care in high-resource settings. Hospital based deliveries will commonly use IV Oxytocin and often fluids as well to help manage the risk of hemorrhage. Furthermore, these facilities have the ability to use more invasive techniques such as balloon tamponade, various types of surgery and uterine artery embolization to control hemorrhage if AMSTL fails.

     

    Current use in low-Resource Settings

    Correct use of AMTSL has been observed in about 1 in ten cases in public hospitals in Nicaragua and about 60% of cases in Benin as well as a variety of rates in between in a study of seven low income countries. AMTSL is also uncommon among home birth attendants, though the practices are encouraged by the WHO. However, this practice requires training for the proper use of uterotonics, cord traction and massage.

    REPRESENTATIVE DEVICES

    MAKE
    Dose
    PRICE
    TECH
    STATUS
    NOTES

    Oxytocin/Uniject

    10 IU
    $0.80-$1.00
    Limited
    Undergoing market expansion

    Oxytocin

    10 IU
    $0.15-$0.25
    Marketed
    Widely used, requires refrigeration

    Ergometrine

    1mg
    $0.35-$0.60
    Marketed
    Requires refrigeration

    Synometrine

    5IU + 0.5mg
    $0.45-$0.70
    Marketed
    Oxytocin + ergometrine

    Misoprostol

    600 mcg
    $0.42-$3.60
    Marketed
    Potentially self-administrated

    *Prices are approximated. Actual pricing can and will vary with market conditions.

  • CHARACTERISTICS OF REPRESENTATIVE PRODUCT

    TECHNOLOGY CHARACTERISTICS

    OPERATIONAL PARAMETERS

    POTENTIAL OPPORTUNITIES FOR IMPROVEMENT

    SKILLS

    REQUIRED

    Intended end user
    Training required
    Time required per use
    Skilled birth attendant
    Course to become a skilled birth attendant which includes training in AMTSL
    N/A

    ENVIRONMENT/ INFRASTRUCTURE

    Power required
    Waste collection
    Complementary technologies required
    Temperature and storage
    Maintenance
    None
    Heat stable product
    N/A

    The primary technology associated with AMTSL is uterotonics.

    COST

    Cost to train (approximate)
    Cost/course (approximate)
    $20-$200 per person
    <$5

    Cost to train is an estimate of the marginal cost to add AMTSL to a skilled birth attendant training. Cost/course is primarily the cost of the uterotonic.

    OTHER

    Portability
    Regulatory
    Efficacy
    <200g (weight of drug with packaging)
    Uterotonics and skilled birth attendants regulated differently in different countries
    Can reduce the risk of postpartum hemorrhage by 62%

Sources: US Department of Health and Human Services, "Active Management of the third stage of labor: prevention and treatment of postpartum hemorrhage"http://guideline.gov/content.aspx?id=15263. WHO: "Use of active management of the third stage of labor in seven developing countries" http://www.who.int/bulletin/volumes/87/3/08-052597/en/index.html